Purpose: This phase II study was undertaken to define the efficacy and toxicity of pemetrexed in combination with gemcitabine in patients with metastatic breast cancer.
introduction
Pemetrexed is a novel folate antimetabolite [1] . It inhibits a number of folate-dependent enzymes, including thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase, involved in de novo purine and pyrimidine synthesis [2] . Single-agent pemetrexed has demonstrated activity in a variety of tumor types in phase II studies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . A response rate of 10-28% has been observed in patients with advanced breast cancer, including those with prior treatment with an anthracycline and paclitaxel [6, [15] [16] [17] [18] [19] . The major toxicities of pemetrexed are myelosupppression, skin rash and mucositis, with neutropenia being the primary dose-limiting toxicity. Transient grade 3 and 4 elevations of liver transaminases are common but not dose-limiting. An elevated level of plasma homocysteine was found to be a significant risk factor for treatment-related toxicities. Supplementation with vitamin B 12 and folic acid has been shown to lower plasma homocysteine level, and ameliorate the toxicity of pemetrexed [3, 16] .
Gemcitabine (difluorodeoxycytidine) is a novel pyrimidine antimetabolite [20] , which has broad activity in a variety of solid tumors [21] . In several phase II studies, the response rate of patients with metastatic breast cancer treated with gemcitabine has ranged from 29% (second-line therapy) to 38% (first-line therapy) [22, 23] . Using HCT-8 colon carcinoma cells for clonogenic studies, sequence-dependent cytotoxic synergy was demonstrated between gemcitabine and pemetrexed [24, 25] . A subsequent phase I study of the combination of gemcitabine and pemetrexed was undertaken [24] [25] [26] . The most common toxicity was neutropenia, which was dose-limiting.
The recommended dose and schedule of this combination for subsequent phase II testing was gemcitabine 1250 mg/m 2 given on days 1 and 8 with pemetrexed 500 mg/m 2 given on day 8, 90 min after completion of the gemcitabine infusion.
Based on the antitumor activity of gemcitabine and pemetrexed as single agents in metastatic breast cancer, as well as the synergic cytotoxic effect of these two agents observed in preclinical studies, a phase II study was performed to evaluate the combination of these two agents in metastatic breast cancer. The goals of this study were to assess the efficacy and toxicity of this combination in patients with metastatic breast cancer who had received an anthracycline and a taxane in either the adjuvant or metastatic setting, and to describe the overall survival and time to disease progression.
patients and methods

patient selection
Women with histological or cytologic confirmed bidimensionally measurable breast cancer with clinical evidence of metastatic disease were eligible for this study if they met the following criteria: they must have previously received an anthracycline and a taxane or a combination of both, in the adjuvant or metastatic setting; they must not have received more than one chemotherapy regimen for metastatic disease (unless these were a taxane and anthracycline); age ‡18 years; Eastern Cooperative Oncology Group performance status £2; adequate bone marrow (platelets ‡100 · 10 9 cells/l, absolute neutrophil count ‡1.5 · 10 9 cells/l), hepatic (total bilirubin £2· the upper limit of normal; aspartate transaminase £3· the upper limit of normal or £5· the upper limit of normal if metastatic disease was present in the liver) and renal functions (estimated creatinine clearance ‡45 ml/min); albumin ‡3 g/dl; and a life expectancy of ‡3 months. Exclusion criteria included: diagnosis of another malignancy within the past 5 years (except basal cell or squamous cell skin cancer and adequately treated non-invasive carcinomas); prior treatment with gemcitabine, pemetrexed or strontium 89; uncontrolled infection or any chronic debilitating disease; clinically significant effusions (pericardial, pleural, ascites) unless these could be drained; body surface area >3 m 2 ; aspirin or NSAIDs £2 days prior to pemetrexed administration; major surgery or any immunologic, genetic, radiation or chemotherapy <4 weeks prior to randomization; more than three prior chemotherapy regimens; radiation therapy to >25% of the bone marrow; and known brain metastasis. Written informed consent was obtained according to federal and institutional guidelines.
experimental treatment
Pemetrexed and gemcitabine were supplied as lyophilized powder forms by Eli Lilly & Company through the NCCTG Coordinating Center Pharmacy. These agents were then reconstituted in sodium chloride solution prior to use. Gemcitabine 1250 mg/m 2 was given intravenously in 250 ml of normal saline over 30 min on days 1 and 8 and pemetrexed 500 mg/m 2 was given intravenously in 100 ml of normal saline over 10 min, 90 min after the end of gemcitabine infusion on day 8 of a 3-week cycle; 350-600 lg of folic acid was given orally daily and 1000 lg of vitamin B 12 was given intramuscularly every 9 weeks starting 7 days prior to the first dose and until 3 weeks after the last dose of pemetrexed; 4 mg of dexamethasone was given orally every 12 h on the day before, day of and day after all doses of pemetrexed. Antiemetics were given before chemotherapy on days 1 and 8 according to institutional guidelines. Colony-stimulating factors were not used prophylactically to prevent granulocytopenia. Treatment continued until disease progression, unacceptable toxicity or two cycles beyond identification of a complete response (CR). All toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (version 2.0).
clinical care of patients
Complete patient histories, physical examinations, complete blood cell counts, chemistries (aspartate aminotransferase, total bilirubin, creatinine, albumin), calculated creatinine clearance, homocysteine level and chest X-ray were performed at baseline and, with the exception of chest X-ray, prior to each course of treatment. Complete blood cell count was repeated weekly while patients were on study. Radiological studies (roentgenograms, computed axial tomographic scans or magnetic resonance imaging) were performed at baseline and after every two cycles of therapy to assess tumor response. A CR was defined as complete disappearance of all measurable disease. Partial response (PR) was defined as at least 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. Progression was defined as 50% increase or an increase of 10 cm 2 (whichever is smaller) in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) or appearance of any new lesion, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). Stable disease (SD) was documented when there was persistence of disease without meeting the criteria for progression, PR or CR.
statistical design
This was a single-stage phase II study with an interim analysis, conducted to assess the efficacy and toxicity of pemetrexed in combination with gemcitabine. A treatment success was defined as either a CR or PR observed on two consecutive evaluations at least 4 weeks apart.
The trial was designed to test the null hypothesis that the true treatment success rate is at most 0.15. The smallest treatment success proportion that would imply this regimen warrants further study was 0.30. The planned accrual for this Simon design [27] was 55 evaluable patients. An interim analysis was conducted after the first 19 patients had been followed for 6 months. Accrual was not suspended while the first 19 patients were followed for 6 months. If three or fewer responses were observed during the interim analysis, the study was to be closed permanently. If four or more confirmed responses were observed during the interim analysis, accrual was to continue. At the time of the final analysis, a confirmed response among 13 or more of the 55 evaluable patients would suggest that this regimen merits further investigation.
Time to progression was defined as the time from registration to the date of progression. Patients who died without disease progression were censored at the date of their last evaluation. If a patient died without documentation of disease progression, the patient was considered to have had tumor progression at the time of death, unless there was sufficient documented evidence to conclude that progression did not occur prior to death. Survival was defined as the time from registration to death due to any cause. The distribution of time to progression and survival time was estimated using the Kaplan-Meier method [28] . Confidence intervals (CI) for the true treatment success rate were constructed according to the method of Duffy and Santner [29] . Table 1 . The majority of women were postmenopausal (78%) and had visceral metastasis (86%). The number of prior adjuvant chemotherapy regimens was 0 (five patients, 8%) or 1 (54 patients, 92%). The number of prior metastatic chemotherapy regimens was 0 (23 patients, 39%), one (35 patients, 59%) or two (one patient, 2%). Among those who received gemcitabine/pemetrexed as the first-line therapy for metastatic disease, 35% were within 6 months of completing the adjuvant chemotherapy. Twenty-eight (48%) had received prior hormonal therapy. Three hundred and sixty-two doses of treatment were administered throughout the study with a median of five cycles per patient (range one to 22). All 59 patients have discontinued study treatment. The reasons for discontinuing treatment include disease progression (37 patients, 63%), toxicity (nine patients, 15%), patient refusal (eight patients, 14%), alternate treatment (one patient, 2%), physician discretion (three patients, 5%) and death (one patient, 2%). The death on treatment was due to disease progression.
toxicities Any adverse event deemed at least possibly related to treatment was defined as a toxicity and is included in these analyses. Toxicity data were available for all patients. The frequency and severity of the grade 3 and 4 toxicities (occurring in at least 5% of all patients) are shown in Table 2 .
hematological toxicity
Neutropenia was the most common and severe hematological toxicity. Without prophylactic colony-stimulating factors support, 17% of patients had absolute neutrophil count nadir values constituting grade 3 toxicity, 66% had grade 4 toxicity and 14% had febrile neutropenia. Thrombocytopenia was also common, with 24% grade 3 and 3% grade 4 observed. Severe anemia occurred less frequently, with incidences of 2% grade 3 and 0% grade 4. Only 5% of patients required packed red blood cell transfusion.
non-hematological toxicity
Among the grade 3 and 4 non-hematological toxicities, fatigue (17%) and dyspnea (15%) were most common, followed by rash (7%) and anorexia (5%). Other grade 3 and 4 non-hematological toxicities were edema (3%), nausea (3%), stomatitis (2%) and vomiting (2%).
correlation between homocysteine level and toxicity
Homocysteine levels were available for 56 patients at baseline (pretherapy) and 27 patients at cycle 2. No significant difference was observed between the median homocysteine levels of 8 lM (range 3-17) at base line and 8 lM (range 6-16) at cycle 2. The correlation between baseline homocysteine level and treatmentrelated toxicity was studied. Since very few patients had homocysteine level >12 lM, 10 lM was used as the cut-off point for analysis. As shown in Table 3 , 89% (40/45) of patients with a baseline homocysteine level £10 lM and 91% (10/11) of those with a baseline homocysteine level >10 lM experienced a grade 3 or 4 hematological toxicity (P value for difference = 0.85). Similarly, 58% (26/45) of patients with a baseline homocysteine level £10 lM and 64% (7/11) of those with a homocysteine level >10 lM had a grade 3 or grade 4 non-hematological for gemcitabine and 500 mg/m 2 for pemetrexed during cycles 1 and 2. Thirty-two per cent of the patients required a dose reduction after cycle 1, primarily due to hematological nadirs (88%), and 30% of patients required a dose reduction in cycles 4-8. Complete dose information for cycles 1-8 is presented in Table 4 .
clinical activity
Overall, 14 (24%; 95% CI 16% to 39%) patients achieved a PR with a median duration of 8.3 months (range 1.6-16.9). Nine (15%; 95% CI: 5% to 32%) patients had SD for >6 months, with a median of 11 months (range 6.7-36.6). The median survival time was 10.3 months (95% CI 8.3-18.9) and the 1-year survival rate was 49% (95% CI 38% to 64%). The median time to progression was estimated to be 3.7 months (95% CI 2.3-5.3). The Kaplan-Meier curves for overall survival and time to progression are shown in Figure 1 . discussion Metastatic breast cancer is expected to develop in approximately half of the women who will be diagnosed with breast cancer in 2004 [30] . In spite of the availability of several hormonal or chemotherapeutic agents, 90% of patients who develop metastatic breast cancer are expected to die within 5 years, with an overall median survival of only 18-24 months. Several classes of cytotoxic agents, including anthracyclines and taxanes, are currently available to be used either singly or in combination. In the first-line setting, the response rates of individual chemotherapy agents range from 20% to 50%. In the secondline setting, these response rates drop to 15-20%. Even in those patients who achieve an objective response, the median time to progression is around 3-8 months. Combination chemotherapy regimens result in higher response rates; however, significant prolongation in overall survival is yet to be demonstrated. In addition, the increasing use of anthracyclines and taxanes in the adjuvant setting has limited further chemotherapy options in relapsed disease. The testing of novel agents and combinations in metastatic breast cancer, especially for tumors that were previously treated with anthracycline and taxane, is therefore warranted.
Pemetrexed is a novel antifolate that has demonstrated promising antitumor activity in breast cancer, including in anthracycline-and taxane-pretreated tumors. Its excellent tolerability, including lack of alopecia and modest levels of myelosuppression, nausea and mucous membrane toxicity, makes it an attractive candidate for combination therapies. The synergic effect of pemetrexed and gemcitabine observed in preclinical studies provided the rationale for combining these two agents in clinical trials. The present report describes a phase II study of pemetrexed in combination with gemcitabine in the treatment of patients with metastatic breast cancer who have received a prior anthracycline and a taxane in the adjuvant or metastatic setting, or a combination of both. The results of this study are encouraging, with an overall response rate of 24% (95% CI 16% to 39%). This finding met the predefined efficacy parameter of at least 13 responses in 55 patients. It produced a clinical benefit (PR + SD ‡6 months) in 39% of patients. The median survival time was 10.3 months (95% CI 8.3-18.9) and the 1-year survival rate was 49% (95% CI 38% to 64%). The median time to progression was estimated to be 3.7 months (95% CI 2.3-5.3).
This is the first study with pemetrexed in combination with gemcitabine in patients with metastatic breast cancer who were previously treated with an anthracycline and a taxane. Spielmann et al. [31] reported a subset analysis of a phase II study with single-agent pemetrexed in 31 metastatic breast cancer patients previously treated with an anthracycline and a taxane. A higher dose of pemetrexed at 600 mg/m 2 was given intravenously every 21 days. The overall response rate (26%), median duration of response (5.4 months) and median survival (12.8 months) appeared to be similar to the result from our combination regimen. However, it is difficult to draw any conclusions because different doses of pemetrexed were used and the number of patients was small in both studies. Singleagent gemcitabine is also active in metastatic breast cancer. In patients who have previously received an anthracycline and a taxane, the response rate of single-agent gemcitabine has ranged from 0% to 18% in phase II studies [32] [33] [34] [35] . Again, it is difficult to compare these results with our phase II study because of the relative small number of patients in these phase II studies and potential differences in the patient population. Future studies comparing the combination of pemetrexed and gemcitabine with either pemetrexed or gemcitabine alone in a larger patient population would seem to be a reasonable approach.
The most common grade 3/4 toxicity for the combination of pemetrexed and gemcitabine in this phase II study was neutropenia, occurring in 83% of patients (17% grade 3, 66% grade 4), which is higher than that observed in the subset analysis of a phase II study with single-agent pemetrexed in a similar patient population [31] . In that study, grade 3/4 neutropenia was experienced in 58% of patients (26% grade 3, 32% grade 4). The higher incidence of toxicity in our study is to be expected with the combination regimen. The tolerability may improve with dose adjustment of gemcitabine to the standard 1000 mg/m 2 rather than 1250 mg/m 2 used in this study. The sequencing of pemetrexed and gemcitabine administration has been shown to be important for this combination with regards to toxicity and efficacy [25, 36] . 
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A randomized phase II trial reported recently by our group compared three different schedules of pemetrexed and gemcitabine in patients with advanced non-small-cell lung cancer [36] . The schedule of pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8 was found to induce less toxicity with possibly better efficacy when compared with the other two schedules, one of which was similar to what was used in the present study. Therefore, modification of the treatment schedule might result in a better efficacy and tolerability for this combination in patients with metastatic breast cancer. It may also be reasonable to omit the 90-min interval between the infusions of pemetrexed and gemcitabine, since no pharmacokinetic interactions were observed between these two agents in a phase IB study reported recently by our group [37] . Previous studies indicated that pretherapy homocysteine levels were an important predictor of severe toxicities for singleagent pemetrexed in the absence of vitamin B 12 and folic acid supplementation. In this phase II study of the combination of pemetrexed and gemcitabine, all patients received vitamin supplementation. No difference in grade 3 and 4 toxicities was observed among patients with different pretherapy homocysteine levels. This result is to be expected because of the use of vitamin supplementation. It is also important to note that most of our patients had homocysteine levels of <10 lM at baseline, indicating a relatively good nutritional status for this patient population. It is unclear whether vitamin supplementation offers any additional protective effects in patients with homocysteine levels of <10 lM.
The efficacy and tolerability of pemetrexed in combination with gemcitabine is comparable to other chemotherapy options for this patient population. Vinorelbine yielded a response rate of 32% and overall survival of 15.5 months in patients who had received prior treatment with anthracyclines. Grade 3/4 neutropenia occurred in 78% and asthenia in 13% of patients [38] . Capecitabine may be the best tolerated chemotherapeutic agent in this patient population. The most common grade 3 or 4 toxicities of capecitabine were diarrhea (14%) and hand-foot syndrome (10%). It had a response rate of 20%, median time to progression of 3.1 months and median overall survival of 12.8 months in patients with paclitaxel-resistant and anthracycline-exposed breast cancer [39] .
In conclusion, our study provides another viable treatment option for patients with metastatic breast cancer who have been treated with anthracyclines and taxanes. Future studies using lower doses of gemcitabine at 1000 mg/m 2 and modification of administration schedules for the combination of pemetrexed and gemcitabine are needed in a larger patient population to evaluate the efficacy and tolerability.
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